Leef Brands (LEEEF) Income towards Parent Company (2025 - 2026)
Leef Brands (LEEEF) posted Income towards Parent Company of -$426253.0 for Q1 2026, down 260.38% sequentially from $265776.0 in Q1 2025, and down 260.38% YoY from $265776.0 in Q1 2025.
Leef Brands (LEEEF) Income towards Parent Company (2025 - 2026) Analysis & Trends
Leef Brands has reported Income towards Parent Company for 2 years, with the latest figure at -$426253.0 in Q1 2026.
- Quarterly Income towards Parent Company fell 260.38% year-over-year to -$426253.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160477.0 (changed N/A YoY) and the FY2025 annual result came in at -$17.6 million, up 28.77% from the prior year.
- Income towards Parent Company fell to -$426253.0 in Q1 2026 per LEEEF's latest filing, from $265776.0 in the prior quarter.
- Over five years, Income towards Parent Company peaked at $265776.0 in Q1 2025 and troughed at -$426253.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Leef Brands | 58.70 Mn | 53.75 Mn | 2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 Mn |
| Mar 31, 2026 | -426,253.00 |
| Mar 31, 2025 | 265,776.00 |